from some patients with chronic phase CML shows Ph− proplantation in chronic myeloid leukemia (CML) to enrich for norgenitors after 2-4 weeks of culture with rapid decline of the mal cells is a novel approach that may improve survival for source of normal pre-progenitors.
Introduction with recently diagnosed CML as approved by the Human Ethics Committee of the Royal Adelaide Hospital, Adelaide, Chronic myeloid leukemia (CML) is a clonal disorder of the South Australia. Cells were diluted in Hank's balanced salt hemopoietic stem cell characterized by marked expansion of solution (HBSS; Gibco BRL, Victoria, Australia). Light density the myeloid compartment. The Philadelphia (Ph) chromosome mononuclear cells were collected after centrifugation at 400 g is the unique molecular marker of this disorder resulting from over a Lymphoprep density gradient (1.077 g/dl; Nycomed a balanced translocation between the abl gene on chromoPharma, Oslo, Norway) and washed twice in HBSS. Cells some 9 and the bcr gene on chromosome 22. 1 This results in were then used fresh or cryopreserved in 10% dimethylsula hybrid bcr-abl gene which encodes an abnormal 8.5 kb phoxide, 20% fetal calf serum (FCS) by controlled rate freezmRNA and 210 kd (p210) protein with increased tyrosine kining. Cryopreserved cells were thawed in a waterbath at 37°C ase activity. 2 The one curative therapy is allogeneic bone marand washed twice in thaw solution (Ca ++ Mg ++ -free HBSS: row transplantation but only about 25% of patients are eligible 10 mmol/l acid citrate and 2% bovine serum albumin (BSA; for this because of age and lack of suitable donors.
3 AutologCohn fraction V; Sigma, St Louis, MO, USA)). ous bone marrow transplantation (ABMT) is an alternative therapeutic strategy for some patients with CML but the relapse rate is high. 4 New treatment strategies are therefore Antibody labelling and cell sorting: Cells were dual labneeded.
elled with a fluorescein isothiocyanate (FITC)-conjugated antiThere is evidence that normal cells exist in the bone mar-CD34 − 5′ GGT ACC AGG AGT GTT TCT CCA GAC TG 3′  B2a+ 5′ TTC AGA AGC TTC TCC CTG ACA T 3′  Ca3− 5′ TGT TGA CTG GCG TGA TGT AGT TGC TTG G 3′  CFU-GM assay: Triplicate 1 ml cultures were established Abl 1b+5′ CGC TGA GAA TTC TGG AAG ATC TTG AA 3′ in 35 mm plates in 0.9% methylcellulose in IMDM sup-C2 5′ CTC CAC TGG CCA CAA AAT 3′ plemented with 30% FCS and 3 mmol/l L-glutamine. Cultures Ab+ 5′ CTT CTG GAA AGG GGT ACC TAT TA 3′ were stimulated by 10 ng each of interleukin-1 (IL-1), IL-3, IL-6, granulocyte colony-stimulating factor (G-CSF), granuloFirst step PCR buffer for BCR-ABL consisted of 12.5 mM Tris cyte-macrophage (GM)-CSF, and stem cell factor (SCF) pH 8. The assay is an adap-0.5 M primers B2a+ and Ca3−, 0.25 mM each of dATP, dCTP, tation of the 4-day suspension culture system described by dGTP and dTTP, and 30 U/ml Taq polymerase. Primers C2 Iscove et al 12 and measures generation of nascent CFU-GM and Ab+ were used in second step PCR buffer for ABL. Five as an index of precursors to CFU-GM. Sorted cells were resusmicroliters cDNA was added to 20 l first step PCR mix. PCR pended at 1 × 10 3 /ml in pre-CFU medium (IMDM supwas performed on a PE Cetus DNA thermal cycler. An initial plemented with 30% FCS, 1% BSA, 3 mmol/l L-glutamine and denaturation of 95°C for 3 min was followed by 35 cycles of 5 × 10 −5 mol/l ␤-mercaptoethanol) and placed in 24-well 95°C 1 min, 58°C 1 min, 72°C 1 min followed by a 10 min plates and supplemented with 100 ng G-CSF, 100 ng SCF, extension at 72°C. Product from this reaction was reamplified 20 ng IL-6 and 10 ng IL-3. Cells were incubated at 37°C in with internal primers as above. One microliter of product was 5% CO 2 in a humidified atmosphere and at 7 day intervals added to 19 l second step PCR mix and amplified by the were washed and resuspended with fresh medium and growth same protocol. Reaction products were electrophoresed on a factor. Aliquots of the washed cells were plated in triplicate 2% agarose gel. Colonies in which BCR-ABL was detected in the CFU-GM assay.
were defined as leukemic. BCR-ABL-negative colonies in which ABL was detected were defined as normal. Colonies in which neither product was detected were discarded. The
Colony analysis positive controls used in this reaction were a dilute sample of K562 RNA and known positive colonies from previous reac-RNA extraction:
Individual discrete colonies were hartions. Serial dilution of K562 RNA has established the sensivested and dispersed in 10 l diethylpyrocarbonate (DEPC)-tivity of this reaction at 100 pg RNA which is what would be treated phosphate-buffered saline (PBS). This was transferred found in approximately five cells. Negative RNA controls to 100 l RNAzol (Biotecx Laboratories, Houston, TX, USA)
were KG1A for BCR-ABL and EM2 for ABL. Water controls to which 1 l of glycogen (Boehringer Mannheim, New South were used in both reactions. Multiple positive and negative Wales, Australia) was added. Ten microliters of chloroform controls were run in each batch of reactions to ensure validity was added and the mixture vortexed vigorously for 15 s and of results. A further control was the use of plucked methylplaced on ice for 5 min. This was followed by centrifugation cellulose devoid of colonies to test for false results due to at 12 000 g for 15 min. The aqueous phase was transferred to contaminating non-clonogenic cells. a fresh tube in an equal volume of isopropanol. Samples were stored overnight at −20°C and then centrifuged at 12 000 g for 15 min. Supernatant was removed and the RNA pellet Statistics washed once in 75% ethanol and then centrifuged at 7500 g for 8 min. The pellet was then dried briefly under vacuum for Colony analysis was analysed by 2 contingency tables. 1-2 min and then dissolved in 25 l DEPC water and stored at −70°C. All steps were carried out using plugged pipette tips to prevent contamination. Results
Patient samples
cDNA synthesis:
Half of the RNA (12.5 l) was heated to 65°C for 10 min. cDNA synthesis was achieved by adding 12.5 l of cDNA mixture (80 mM Tris pH 8.3, 120 mM KCl, Five patients with recently diagnosed chronic phase CML were studied (Table 1) . Cytogenetic studies on BM and PB 4.8 mM MgCl 2 , 16 mM DTT, 0.1 mM each of dATP, dCTP, dGTP and dTTP, 1.2 g pdN6 (random hexamers; Pharmacia, showed 100% of metaphases positive for the Ph chromosome. All patients had their PB studied but insufficient BM was colVictoria, Australia), 175 units RNAguard (ribonuclease inhibitor; Pharmacia), and 1000 units M-MLV reverse transcriptase lected for study in two patients. Four patients were studied at diagnosis and the remaining patient had received hydroxyurea (Gibco BRL) to samples and incubating at 37°C for 90 min. Following heating to 65°C for 10 min samples were stored therapy for 3 months. The sort windows used are shown in Figure 1 . The mean at −20°C. Cell proliferative capacity Analysis of progenitors for BCR-ABL
The pattern of cell proliferation in the pre-CFU assay was similar between PB and BM (Figure 2a and 
38
− fraction. The DR + to 96% (Figure 4a ). The one BM sample analyzed from this fraction had 1/6 (17%) BCR-ABL-negative colonies. In conand 38 + populations showed early proliferation with maximal trast, 0-90% (median 20%) (Figure 4b ) of progenitors from the DR + fraction of both PB and BM were BCR-ABL negative. Analysis of the 34 + 38 − fraction in three PB samples showed the majority of progenitors were leukemic. The number of BCR-ABL-negative colonies was 11-24% (Figure 4c ). The number of BCR-ABL-negative colonies from the total 34 + cells was 2/12 (17%) in patient UPN 1992 and 1/16 (6%) in patient UPN 2167 which was no different to the results obtained from the 34 + DR + fraction.
Analysis of pre-progenitors for BCR-ABL
Pre-progenitors were analyzed by assessment of secondary colonies at serial time-points. The majority of colonies derived from the 34 + DR − fraction were BCR-ABL negative by PCR analysis of individual colonies at days 14 and 28. Analysis of PB or BM in four patients at day 14 showed 80-100% (median 92%) of colonies were BCR-ABL negative. At day 28, 85-100% (median 89%) of colonies were BCR-ABL negative ( Table 2) . Analysis of pooled colony results showed significantly more BCR-ABL-negative colonies at days 14 (P = 0.0001) and 28 (P = 0.0001) compared to day 0.
Analysis of colonies from the 34 + 38 − fraction at day 14 showed 23-100% (median 70%) BCR-ABL-negative colonies in the PB or BM of four patients ( Table 2) . Analysis of colonies from four of these samples at day 28 showed 42-100% (median 100%) were BCR-ABL-negative. Pooled colony results from this fraction showed significantly more BCR-ABLnegative colonies at days 14 (P = 0.0001) and 28 (P = 0.0001) compared to day 0.
The 34 + DR + fraction gave rise to very few colonies at days 7 and 14. Analysis in patient 1992 showed 14% and 56%
Figure 3
Total CFU-GM production of BM and PB per 1000 cells plated of sorted cell fractions following stroma-free liquid culture.
BCR-ABL-negative colonies at these time-points, respectively.
No colonies were produced from the 38 + fraction at day 7 or 14.
In patient 1992, the unseparated 34 + cells gave rise to few colonies at day 7 and no colonies at day 14. At day 7, 1/3 (33%) of colonies were BCR-ABL negative. Patient 2167 produced more colonies from unseparated 34 + cells and at day 14, 6/28 (21%) of colonies were BCR-ABL negative.
Discussion
We have demonstrated that pre-progenitors derived from the 34 + DR − and 34 + 38 − fractions of both blood and marrow from patients with early chronic phase CML are predominantly BCR-ABL negative. In contrast, progenitors from these populations showed variable levels of BCR-ABL-negative colonies from the 34 
DR
− population contains normal progenitor cells but they co-exist with leukemic progenitors. This pattern of leukemic involvement within the 34 + DR − progenitors may reflect the stage of disease evolution within individual patients, or differences in the expression of the HLA-DR antigen between leukemias.
Anlaysis of the pre-progenitors from the 34 + DR − fraction showed that the majority derived from both PB and BM are BCR-ABL negative. This is similar to previous results achieved following LTBMC. Stromal-based assays may select for the Phnegative clone independently because of a defect in cell adhesion of Ph-positive progenitors but this bias is not present in a stromal-free system. One explanation for the finding of predominant BCR-ABL-negative colonies in both the 34 + DR − and 34 + 38 − fractions is the failure of the leukemic pre-progenitor to proliferate in liquid culture. However, leukemic colonies were detected in samples studied at day 14 or 28 suggesting leukemic pre-progenitors are capable of proliferating in this culture system. Hence it is likely that there is a real difference in the incidence of BCR-ABL positivity in progenitors and pre-progenitors and that pre-progenitors as defined by 34 + DR − or 34 + 38 − are mostly not leukemic. The demonstration of BCR-ABL-negative pre-progenitors in the 34 + 38 − fraction of PB and BM of patients with chronic phase CML is a new finding. In a study of sorted BM cells in patients with chronic phase CML treated with hydroxyurea or interferon the 34 + 38 − population showed no enrichment for BCR-ABL-negative cells compared to the 34 
38
+ population by FISH analysis.
14 Another report of cytogenetic evaluation of PB or BM of six patients with chronic phase CML showed 1/123 normal metaphases in the 34 + 38 − fraction compared to these published findings. However, the pre-progenitors in this fraction show BCR-ABL-negative colonies with a median of 71% at day 14 and 100% at day 28. lowing CD34 selection with a further 60% recovery following 
